Onderneming Xeris Biopharma Holdings, Inc. Nasdaq
Aandelen
XERS
US98422L1070
Farmaceutische producten
Vakgebied
Aantal werknemers: 377
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Gvoke, Keveyis and Recorlev
93,6
%
| 109 | 99,1 % | 153 | 93,6 % | +40,36% |
Royalty, Contract and Other
6,4
%
| 1 | 0,9 % | 11 | 6,4 % | +971,07% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 110 | 100,0 % | 164 | 100,0 % | +48,68% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 60 | 01-01-05 | |
Paul Edick
CEO | Chief Executive Officer | 67 | 05-10-21 |
Steven Pieper
DFI | Director of Finance/CFO | 47 | 01-01-21 |
John Shannon
PSD | President | 62 | 05-10-21 |
Ken Johnson
CTO | Chief Tech/Sci/R&D Officer | 61 | 01-10-21 |
Allison Wey
IRC | Investor Relations Contact | - | - |
Kevin McCulloch
PRN | Corporate Officer/Principal | - | 01-10-18 |
Beth Hecht
LAW | General Counsel | 60 | 01-10-21 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
John Johnson
BRD | Director/Board Member | 66 | 05-10-21 |
Jeffrey Sherman
BRD | Director/Board Member | 69 | 05-10-21 |
Marla Persky
BRD | Director/Board Member | 68 | 05-10-21 |
Paul Edick
CEO | Chief Executive Officer | 67 | 05-10-21 |
Garheng Kong
BRD | Director/Board Member | 49 | 01-10-21 |
John Schmid
BRD | Director/Board Member | 60 | 05-10-21 |
Director/Board Member | 65 | 05-10-21 | |
Dawn Halkuff
BRD | Director/Board Member | 53 | 05-10-21 |
Ricki Fairley
BRD | Director/Board Member | 67 | 27-03-23 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 148 253 615 | 142 712 322 ( 96,26 %) | 0 | 96,26 % |
Bedrijfsgegevens
Xeris Biopharma Holdings, Inc.
1375 West Fulton Street Suite 1300
60607, Chicago
+
http://www.xerispharma.comSector
Verkoop per activiteit
Vaira. 1 jan. | Kapi. | |
---|---|---|
+26,08% | 662 mld. | |
+21,85% | 546 mld. | |
-4,77% | 359 mld. | |
+16,97% | 323 mld. | |
+5,69% | 290 mld. | |
+13,68% | 234 mld. | |
+3,65% | 198 mld. | |
-11,12% | 194 mld. | |
-3,40% | 157 mld. |